{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:12:30Z","timestamp":1784873550755,"version":"3.55.0"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>\n                      Clinically significant alloantibodies complicate transfusion and prenatal care, especially in individuals with genetic variants affecting high\u2010frequency antigens. Many patients from African descent carry\n                      <jats:italic>RHCE*ceVS<\/jats:italic>\n                      alleles, which alter the expression of c (RH4), e (RH5) and hr\n                      <jats:sup>B<\/jats:sup>\n                      (RH31). However, the risk and clinical impact of alloimmunization remain uncertain. We evaluated the alloimmunization in a cohort of patients with a\n                      <jats:italic>RHCE*ceVS<\/jats:italic>\n                      genotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective study on 48 patients with a\n                      <jats:italic>RHCE*ceVS<\/jats:italic>\n                      genotype divided into three categories: prenatal care, patients with sickle cell disease (SCD) and other or unspecified diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No anti\u2010c, anti\u2010e or anti\u2010hr\n                      <jats:sup>B<\/jats:sup>\n                      were found in prenatal care patients or in patients with other or unspecified diagnosis. Among transfused patients with SCD, 50% developed an anti\u2010e. Anti\u2010hr\n                      <jats:sup>B<\/jats:sup>\n                      was identified in two patients, both with SCD. Warm autoantibodies were found in 58% of transfused patients with SCD, many of whom had an anti\u2010e.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The risk of developing anti\u2010e or anti\u2010hr\n                      <jats:sup>B<\/jats:sup>\n                      antibodies was low in patients with an\n                      <jats:italic>RHCE*ceVS<\/jats:italic>\n                      genotype, except in those with SCD. In patients with SCD, the presence of autoantibodies, recent transfusions and technical caveats complicate the assessment of clinical impact; therefore, an individualized evaluation of alloimmunization risk is recommended.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70193","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T02:10:59Z","timestamp":1770171059000},"page":"649-653","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with\n                    <scp>\n                      <i>RHCE<\/i>\n                    <\/scp>\n                    variants"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-1443","authenticated-orcid":false,"given":"Gabriel Andr\u00e9","family":"Leiva\u2010Torres","sequence":"first","affiliation":[{"name":"Hema\u2010Quebec, Transfusion Medicine  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Baillargeon","sequence":"additional","affiliation":[{"name":"Hema\u2010Quebec, Transfusion Medicine  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Constanzo\u2010Yanez","sequence":"additional","affiliation":[{"name":"Hema\u2010Quebec, Transfusion Medicine  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Robitaille","sequence":"additional","affiliation":[{"name":"Hema\u2010Quebec, Transfusion Medicine  Montreal Qu\u00e9bec Canada"},{"name":"Division of Hematology\u2010Oncology, Department of Pediatrics CHU Sainte\u2010Justine  Montreal Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.270546"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-379"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17778"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-851360"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/aob-20-84"},{"key":"e_1_2_9_7_1","unstructured":"ISBT \u2010 Red Cell Immunogenetics and Blood Group Terminology.International Society of Blood Transfusion. Available from:https:\/\/www.isbtweb.org\/working-parties\/red-cell-immunogenetics-and-blood-group-terminology. Last accessed 9 Jul 2025."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000490858"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2024.09.1463"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490623"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16518"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02382.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:47:46Z","timestamp":1778892466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/vox.70193"],"URL":"https:\/\/doi.org\/10.1111\/vox.70193","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}